+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials



Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials



Clinical and Applied Thrombosis/Hemostasis 23(6): 685-695



In randomized controlled trials, non-vitamin K antagonist oral anticoagulants (NOACs) demonstrated noninferiority to vitamin K antagonists (VKAs) in patients who spent limited time in therapeutic range (TTR). In real-life patients, TTR is known to vary significantly across countries and health-care settings. We aim to evaluate the quality of VKA treatment in Swiss primary care (PC) by comparing patients' median TTR to levels achieved in the phase III NOAC trials RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF-TIMI 48. Patient characteristics affecting TTR control shall be estimated. This is a retrospective longitudinal study in Swiss PC patients receiving VKA for ≥6 months. We identified patients from the PC research database FIRE (Family medicine International Classification of Primary Care Research using Electronic medical records) and calculated TTR according to Rosendaal formula. Comparative data from NOAC trials were retrieved from medical literature. Linear regression models were used to assess predictors of TTR. Primary care encounters of 215 patients were analyzed. Like in the NOAC trials, median observation period was 2.2 years, but patients were older (67.9% vs 38% ≥75 years) and differed in terms of concomitant diseases and drugs. Median TTR was 75% (65% in the NOAC trials). Female sex was independently associated with a lower TTR and significantly modified by increasing age. Practitioners should consider that patients in NOAC trials are only partly representative of PC patients, particularly in terms of TTR control. Only a minority of the observed patients would require a therapy switch to NOACs due to inadequate TTR. Further research is needed in order to identify specific features of care management that are associated with these outcomes.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057211329

Download citation: RISBibTeXText

PMID: 27056934

DOI: 10.1177/1076029616642514


Related references

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children. Journal of Thrombosis and Haemostasis 9(5): 1090-1092, 2011

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis 9(11): 2331-2332, 2012

Comparison of 'time within therapeutic INR range' with 'percentage INR within therapeutic range' for assessing long-term anticoagulation control in children: a rebuttal. Journal of Thrombosis and Haemostasis 9(11): 2332-2333, 2012

Time in Therapeutic Range and Percentage of International Normalized Ratio in the Therapeutic Range as a Measure of Quality of Anticoagulation Control in Patients With Atrial Fibrillation. Canadian Journal of Cardiology 32(10): 1247.E23-1247.E28, 2016

Control of anticoagulation with vitamin K antagonists: overestimation of median time in therapeutic range when assessed by linear interpolation. Thrombosis and Haemostasis 116(4): 679-686, 2016

Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circulation. Cardiovascular Quality and Outcomes 4(1): 22-29, 2011

Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. European Heart Journal 32(18): 2282-2289, 2011

Therapeutic quality control of follow-up of oral anticoagulation in primary care: 4-year experience. Atencion Primaria 15(9): 555-560, 1995

Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic range. Current Medical Research and Opinion 24(5): 1455-1458, 2008

Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina. Clinical and Applied Thrombosis/Hemostasis 23(5): 445-453, 2017

Use benchmarks to allocate time in primary care practice. Capitation Rates & Data 13(1): 8-10, 2008

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. Journal of Clinical Oncology 26(4): 527-534, 2008

Control of oral anticoagulation. The therapeutic range. Therapeutische Umschau. Revue Therapeutique 34(5): 355, 1977

Control of oral anticoagulation--therapeutic range. Schweizerische Medizinische Wochenschrift 107(37): 1308, 1977

Comparison of warfarin time in the therapeutic range at a pharmacist-run anticoagulation clinic and the RE-LY trial. American Journal of Health-System Pharmacy 72(7): 557-562, 2015